Jadwal Sholat

Memuat jadwal sholat…

Kedokteran & Kesehatan editorial

Open AccessOA2022

The Staphylococcus aureus Network Adaptive Platform Trial Protocol: New Tools for an Old Foe

The SNAP trial is an adaptive platform trial designed to efficiently evaluate multiple treatment strategies for Staphylococcus aureus bloodstream infection, aiming to enroll 7000 participants across multiple countries.
Steven Y. C. Tong; Jocelyn M. Mora; Asha C. Bowen; Matthew P. Cheng; N. Daneman; Anna L. Goodman; George S. Heriot; Todd C. Lee; Roger J. Lewis; D. Lye; R. Mahar; Julie A. Marsh; A. McGlothlin; Zoe K. McQuilten; S. Morpeth; David L. Paterson; David J. Price; Jason A. Roberts; J. Robinson; S. V. van Hal; G. Walls; Steve A. Webb; Lyn Whiteway; D. Yahav; Joshua S. Davis· Clinical Infectious Diseases· 2022· DOI 10.1093/cid/ciac476

The core problem

Staphylococcus aureus bloodstream (SAB) infection is a common and severe infectious disease, with a 90-day mortality of 15%–30%. Despite this high mortality, fewer than 3000 people have been randomized into clinical trials of treatments for SAB infection. The limited evidence base partly results from clinical trials for SAB infections being difficult to complete at scale using traditional clinical trial methods. Traditional trials often focus on a single question, require large sample sizes, and are costly and slow. The Staphylococcus aureus Network Adaptive Platform (SNAP) trial was designed to address these challenges by using an adaptive platform design that enables multiple questions to be answered efficiently. The SNAP trial commenced enrolling patients across multiple countries in 2022 with an estimated target sample size of 7000 participants. This approach may serve as an exemplar to increase efficiency of clinical trials for other infectious disease syndromes.

Innovation

The SNAP trial is an adaptive platform trial, a type of clinical trial design that allows for simultaneous evaluation of multiple interventions and adaptation of the trial based on accumulating data. Key design features include:

- **Platform structure**: The trial is organized around a master protocol with multiple domains, each addressing a different question about SAB management (e.g., antibiotic choice, duration, adjunctive therapies).
- **Adaptive randomization**: Participants are randomized to available treatment options within each domain, with randomization probabilities updated based on emerging evidence to favor more effective treatments.
- **Bayesian analysis**: The trial uses Bayesian statistical methods to incorporate prior knowledge and to allow for frequent interim analyses and adaptation.
- **Shared control group**: A common control group is used across domains to increase efficiency and reduce sample size.
- **Broad eligibility**: The trial aims to enroll a diverse population of patients with SAB infection across multiple countries.

The trial targets a sample size of 7000 participants, which is substantially larger than previous SAB trials, to provide adequate power to answer multiple questions. The adaptive design allows for dropping ineffective treatments early and adding new questions as needed.

Mathematically, the adaptive randomization can be represented as:

where represents the current evidence for treatment (e.g., posterior probability of benefit). This ensures that more participants are assigned to treatments that appear more promising.

A Mermaid diagram illustrating the platform structure is shown below:

Introduction
Staphylococcus aureus bloodstream (SAB) infection is a common and severe infectious disease, with a 90-day mortality of 15%–30%. Despite this high mortality, fewer than 3000 people have been randomized into clinical trials of treatments for SAB infection. The limited evidence base partly results from clinical trials for SAB infections being difficult to complete at scale using traditional clinical trial methods. Traditional trials often focus on a single question, require large sample sizes, and are costly and slow. The Staphylococcus aureus Network Adaptive Platform (SNAP) trial was designed to address these challenges by using an adaptive platform design that enables multiple questions to be answered efficiently. The SNAP trial commenced enrolling patients across multiple countries in 2022 with an estimated target sample size of 7000 participants. This approach may serve as an exemplar to increase efficiency of clinical trials for other infectious disease syndromes.

Why it matters

The SNAP trial represents a paradigm shift in the design of clinical trials for infectious diseases. By using an adaptive platform, it addresses the inefficiencies of traditional trials, which often fail to complete at scale for severe infections like SAB. The platform approach allows multiple questions to be answered simultaneously, with shared infrastructure and a common control group, reducing costs and time. The Bayesian framework facilitates the integration of prior knowledge and enables continuous learning. The trial's broad eligibility criteria and multinational participation enhance generalizability. Challenges include the complexity of coordination, the need for robust data systems, and the potential for operational biases. Nevertheless, the SNAP trial serves as an exemplar for other infectious disease syndromes, demonstrating how adaptive platform trials can efficiently generate high-quality evidence to improve patient care. The success of SNAP could pave the way for similar designs in other areas of medicine.

Who should read this

Pembaca Research Digest dan praktisi rumpun ini.

Opening member content…